loadpatents
Patent applications and USPTO patent grants for Kudirka; Romas.The latest application filed is for "immunoconjugates targeting pd-l1".
Patent | Date |
---|---|
Immunoconjugates Targeting HER2 App 20220226492 - Ackerman; Shelley Erin ;   et al. | 2022-07-21 |
Immunoconjugates Targeting PD-L1 App 20220226491 - Ackerman; Shelley Erin ;   et al. | 2022-07-21 |
Anti-cea Immunoconjugates, And Uses Thereof App 20220195066 - Ackerman; Shelley Erin ;   et al. | 2022-06-23 |
Immunoconjugates Targeting CEA App 20220152215 - Ackerman; Shelley Erin ;   et al. | 2022-05-19 |
Macromolecule-Supported TLR Agonists App 20220143012 - Ackerman; Shelley Erin ;   et al. | 2022-05-12 |
Thienoazepine Immunoconjugates, And Uses Thereof App 20210128744 - Kudirka; Romas ;   et al. | 2021-05-06 |
Aminobenzazepine Compounds, Immunoconjugates, And Uses Thereof App 20200390899 - Ackerman; Shelley Erin ;   et al. | 2020-12-17 |
Nucleoside analog libraries Grant 7,034,147 - Epple , et al. April 25, 2 | 2006-04-25 |
Nucleoside analog libraries App 20040006176 - Epple, Robert ;   et al. | 2004-01-08 |
Nucleoside analog libraries App 20030225205 - Epple, Robert ;   et al. | 2003-12-04 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.